Case Report
Victoria E. Wang, Anatoly Urisman, Lee Albacker, Siraj Ali, Vincent Miller, Rahul Aggarwal and David Jablons
Journal for ImmunoTherapy of Cancer 2017, 5:75 (19 September 2017)
From the Authors
"Our article highlights the robust and durable response of a case of large cell neuroendocrine carcinoma, a rare and aggressive tumor, to checkpoint inhibitor therapy."
Victoria Wang, MD, PhD — University of California, San Francisco
Meeting Report
Andrew Zloza, A. Karolina Palucka, Lisa M. Coussens, Philip J. Gotwals, Mark B. Headley, Elizabeth M. Jaffee, Amanda W. Lund, Arlene H. Sharpe, Mario Sznol, Derek A. Wainwright, Kwok-Kin Wong and Marcus W. Bosenberg
Journal for ImmunoTherapy of Cancer 2017, 5:77 (19 September 2017)
From the Authors
"With a rapidly increasing number of newly discovered immune and cancer cell pathways and mediators, models for unraveling basic mechanisms and vetting potential drugs are needed. Thus, we held this workshop to discuss in an open forum the advantages and disadvantages of current models and to highlight future needs. The result was a shared appreciation of the vital tools with which current models (including transplantable tumor, genetically engineered, and humanized mouse) provide the field of cancer immunology and immunotherapy. A resounding call was made for further innovation in modeling to meet the demands of testing combinatorial cancer therapies, understanding the tumor microenvironment, predicting outcomes and toxicity, and utilizing cancer patient-derived tissues for impactful translation from pre-clinical observation to clinical cure."
Andrew Zloza, MD, PhD — Rutgers Cancer Institute of New Jersey
Research Articles
Veronika Kremer, Maarten Ligtenberg, Rosa Zendehdel, Christina Seitz, Annet Duivenvoorden, Erik Wennerberg, Eugenia Colón, Ann-Helén Scherman-Plogell and Andreas Lundqvist
Journal for ImmunoTherapy of Cancer 2017, 5:73 (19 September 2017)
From the Authors
"Clinical responses of NK cell-based therapies in patients with solid tumors are potentially limited by ineffective homing of the infused NK cells to the tumor site. Here we show that genetic modification of human primary NK cells to re-express the chemokine receptor CXCR2 is a promising strategy to enhance their migration to recombinant CXCR2 ligands and RCC tumor supernatants and thereby improve anti-tumor responses."
Andreas Lundqvist, PhD — Karolinska Institutet
Howard L. Kaufman, Robert H. I. Andtbacka, Frances A. Collichio, Michael Wolf, Zhongyun Zhao, Mark Shilkrut, Igor Puzanov and Merrick Ross
Journal for ImmunoTherapy of Cancer 2017, 5:72 (19 September 2017)
From the Authors
"Finding appropriate clinical study endpoints that incorporate the true potential of immunotherapy agents is a high priority for the field. In this paper, we show that durable response rate, as used in an oncolytic virus immunotherapy study, was validated as such an endpoint with a positive association with other more standard endpoints. Clinical investigators should consider durable response rate as a clinically meaningful endpoint for clinical protocol development with immunotherapy agents and regimens."
Howard L. Kaufman, MD, FACS — Rutgers Cancer Institute of New Jersey
Rocio Garcia-Carbonero, Ramon Salazar, Ignacio Duran, Ignacio Osman-Garcia, Luis Paz-Ares, Juan M. Bozada, Valentina Boni, Christine Blanc, Len Seymour, John Beadle, Simon Alvis, Brian Champion, Emiliano Calvo and Kerry Fisher
Journal for ImmunoTherapy of Cancer 2017, 5:71 (19 September 2017)
From the Authors
"This phase I study demonstrates for the first time that a group B oncolytic adenovirus can be injected intravenously, survive within the blood stream and then be found replicating extensively in tumor cells. The study is important because it paves the way for using oncolytic virotherapy, including therapeutic transgene-bearing viruses, to treat disseminated disease, avoiding the need for direct injection of each tumor deposit."
Brian R. Champion, PhD — PsiOxus Therapeutics Ltd.
Caroline Tosch, Bérangère Bastien, Luc Barraud, Benoit Grellier, Virginie Nourtier, Murielle Gantzer, Jean Marc Limacher, Eric Quemeneur, Kaïdre Bendjama and Xavier Préville
Journal for ImmunoTherapy of Cancer 2017, 5:70 (19 September 2017)
From the Authors
"Retrospective analysis of samples from the TIME trial, a phase 2 trial evaluating the MUC1-targeted viral based cancer vaccine TG4010 in NSCLC, shows an association between development of specific cell-mediated immune response and patient outcome. Administration of TG4010 correlated with the development of a specific T cell response against MUC1 and with a broadening of the immune repertoire against other tumor-associated antigens leading to extended patient survival."
Kaïdre Bendjama — Transgene
Diwakar Davar, Fei Ding, Melissa Saul, Cindy Sander, Ahmad A. Tarhini, John M. Kirkwood and Hussein A. Tawbi
Journal for ImmunoTherapy of Cancer 2017, 5:74 (19 September 2017)
From the Authors
"Prior to the advent of PD-1 inhibitors, HD IL-2 and adoptive cellular therapies were the most effective means of treating advanced melanoma. While the arrival of PD-1 inhibitors and combinations have transformed the landscape of advanced melanoma, this report of 273 patients from the University of Pittsburgh treated in the modern era identifies some new prognostic factors; and suggests that HD IL-2 may retain a role in the melanoma treatment armamentarium."
Diwikar Davar, MD — University of Pittsburgh Cancer Institute
August Highly Accessed Articles
Dylan J. Martini, Aly-Khan A. Lalani, Dominick Bossé, John A. Steinharter, Lauren C. Harshman, F. Stephen Hodi, Patrick A. Ott and Toni K. Choueiri
Journal for ImmunoTherapy of Cancer 2017, 5:66 (15 August 2017)
Ashish M. Kamat, Joaquim Bellmunt, Matthew D. Galsky, Badrinath R. Konety, Donald L. Lamm, David Langham, Cheryl T. Lee, Matthew I. Milowsky, Michael A. O’Donnell, Peter H. O’Donnell, Daniel P. Petrylak, Padmanee Sharma, Eila C. Skinner, Guru Sonpavde, John A. Taylor III, Prasanth Abraham and Jonathan E. Rosenberg
Journal for ImmunoTherapy of Cancer 2017, 5:68 (15 August 2017)